SYSTEMIC LUPUS ERYTHEMATOSUS

This early-stage study tests a new drug called RO7507062 in 70 people with systemic lupus erythematosus (SLE). The main goal is to check its safety and how the body processes it. Participants receive the drug as a shot under the skin, and the study will look for side effects and …

This study looks at the long-term safety and effectiveness of enpatoran, an experimental drug for lupus. About 379 people who completed a previous 24-week study will take different doses of enpatoran or a placebo for up to 194 weeks. The goal is to see if the drug is safe and hel…

This Phase 2 trial tests whether the experimental drug SAR441344 can safely control disease activity in people with active systemic lupus erythematosus (SLE). About 109 adults aged 18–70 will receive either the drug or a placebo for 24 weeks. The main goal is to see if more peopl…

This early-stage study planned to test a single infusion of CB-010, a CRISPR-edited CAR-T cell therapy made from donor cells, in people with refractory systemic lupus erythematosus (SLE), including those with kidney inflammation. Participants would have received chemotherapy befo…

This phase 3 study tests whether upadacitinib (RINVOQ), a drug already used for arthritis, can safely control moderate-to-severe lupus. About 1,000 adults with lupus will take either the drug or a placebo daily for a year. Researchers will measure how well it reduces disease acti…

This study looks at whether a single 2mL injection of ianalumab works as well as two 1mL injections in people with rheumatoid arthritis, Sjögren's disease, or lupus. About 155 adults will receive the drug both ways to compare how much gets into the body and if it's safe. The goal…

This early-stage study tests a new treatment called CNTY-101 for people with certain autoimmune diseases like lupus, myositis, and scleroderma. The treatment uses specially designed immune cells to target and destroy faulty B cells that attack the body. The main goals are to chec…

This study tests a new treatment using donor immune cells (CAR T-cells) that are engineered to target and destroy faulty immune cells causing lupus or scleroderma. The goal is to control the disease in patients who have not responded to standard therapies. The trial involves 18 a…

This early-phase study tests a new treatment called NKX019 for people with lupus, an autoimmune disease. NKX019 uses specially engineered immune cells to target and calm overactive B cells. The main goal is to check safety in about 6 participants, while also looking for signs tha…

This phase 3 trial tests whether adding sirolimus (rapamycin) to standard treatment helps control active lupus better than placebo. 146 adults with active lupus despite standard care will receive either sirolimus or placebo for 24 weeks, with an option to continue for another 24 …

This early-stage study tests a therapy called SC291, made from donor immune cells, in 7 people with severe lupus or vasculitis that hasn't improved with standard treatments. The goal is to see if it is safe and tolerable, and to get a first look at whether it can control the dise…

This early-stage trial is testing a new treatment for people with severe lupus or scleroderma that hasn't responded to standard therapies. The treatment involves taking a patient's own immune cells, engineering them to target and destroy disease-causing immune cells, and then giv…

This study tests a non-invasive device that uses low-frequency electromagnetic waves to help immune cells communicate better. The goal is to reduce flare-ups in people with lupus, rheumatoid arthritis, or multiple sclerosis. Participants will receive 20-minute sessions three time…

This study tests whether afimetoran can help control active systemic lupus erythematosus (SLE), an autoimmune disease that causes inflammation and damage throughout the body. About 268 adults with lupus will receive either afimetoran or a placebo for 48 weeks to see if the drug r…

This study tests whether the supplement N-acetylcysteine (NAC) can help control lupus, a chronic autoimmune disease. About 290 adults with lupus will first take NAC for 3 months to find a safe dose, then half will continue NAC and half will get a placebo for another 9 months. The…

This study looks back at medical records of 180 adults with lupus to compare two drugs, telitacicept and belimumab. The goal is to see which one works better at controlling the disease and has fewer side effects. Participants are not given any new treatment—the researchers simply…

This early-stage study tests whether a special type of immune cell, called a CAR-T cell, is safe for people with severe lupus that hasn't responded to standard treatments. The cells are designed to target and destroy faulty immune cells that cause lupus. The trial includes 22 chi…

This early-stage study tests a new treatment called RD06-04, which uses a patient's own immune cells modified to target and destroy faulty immune cells. The goal is to see if it is safe and can help control active autoimmune diseases like lupus, scleroderma, and Sjogren's syndrom…

This study tests a new medicine called anifrolumab, given as a shot under the skin, for adults with moderate-to-severe lupus. The goal is to see if it can better control disease activity compared to a placebo, when added to standard treatments. About 367 participants are involved…

This study tests a drug called belimumab, given as a shot under the skin, in children aged 5 to 17 with lupus. The goal is to find the right dose and check if it's safe when used with standard treatments. Lupus is a long-term disease where the immune system attacks the body, and …

This study tests a new treatment called YTB323 for people with severe lupus that hasn't responded to other therapies. YTB323 uses a patient's own immune cells, modified to target and destroy faulty immune cells driving the disease. The trial will enroll 21 adults and focus on saf…

This study looks at the long-term safety of a drug called dapirolizumab pegol for people with systemic lupus erythematosus (lupus). About 760 adults who completed a previous related study will receive the drug and be monitored for side effects over time. The goal is to see if the…

This study tests whether a daily pill called deucravacitinib can safely control lupus symptoms better than a placebo. About 516 adults with active moderate-to-severe lupus will take either the drug or a dummy pill for up to a year. The main goal is to see if more people on the dr…

This study tests whether the drug deucravacitinib can safely control symptoms in people with active moderate-to-severe lupus. About 513 participants will receive either the drug or a placebo. The goal is to see if the drug reduces lupus disease activity better than placebo.

This study tests a new drug called ianalumab for people with active systemic lupus erythematosus (SLE), a chronic autoimmune disease. About 436 participants receive either ianalumab or a placebo as a shot under the skin, once a month or once every three months, along with their u…

This study aimed to test whether the drug telitacicept could help people with moderate-to-severe lupus better than a placebo. It was designed for people aged 12 to 70 with active lupus symptoms. However, the trial was withdrawn before enrolling any participants, so no results are…

This study tests whether lisinopril, a blood pressure drug that works in the brain, can improve memory and concentration in people with lupus. About 36 adults with lupus and cognitive issues will take either lisinopril or another ACE inhibitor for 12 months. Researchers will meas…

This study tests a new medicine called MIL62 in 120 adults with lupus, a chronic autoimmune disease. The goal is to see if MIL62 can reduce disease activity better than a placebo. Participants must have active lupus and be on a stable treatment plan. The study is not a cure but a…

This phase 3 study tests whether adding a monthly injection of ianalumab to standard lupus treatments helps control active disease better than placebo. About 288 people aged 12 and older with systemic lupus erythematosus (SLE) are taking part. The main goal is to see if ianalumab…

This study tests a drug called obinutuzumab in 303 people with active lupus. Participants receive either the drug or a placebo, along with their usual treatments. The goal is to see if obinutuzumab can reduce lupus symptoms and disease activity better than placebo alone.

This early-phase study tests KITE-363, a personalized therapy where a patient's own immune cells are modified to target and attack faulty B cells that drive autoimmune diseases like lupus and scleroderma. About 52 adults with severe, treatment-resistant forms of these conditions …

This study follows 551 people with lupus who are starting anifrolumab for the first time. Researchers will track how well the drug controls disease activity, reduces flares, and improves quality of life over time. The goal is to see if the benefits seen in clinical trials hold up…

This study aimed to test a new type of cell therapy (called CAR T-cells) in people with severe lupus or inflammatory myopathy that did not get better with standard treatments. The therapy uses donor cells to target and destroy faulty immune cells. However, the study was withdrawn…

This study looks at whether the Shingrix vaccine is safe and effective for preventing shingles in people with autoimmune rheumatic diseases like rheumatoid arthritis and lupus. About 2,000 patients will receive the vaccine or a placebo, and researchers will monitor for disease fl…

This study looks at 500 adults with lupus to see if certain immune markers can better predict who will develop heart disease. Participants give blood samples, have ultrasound scans of their neck arteries, and fill out diet and exercise questionnaires. The goal is to improve how d…

This study looks at the safety of the shingles vaccine (HZ/su) in pregnant women aged 18-49 with weakened immune systems. Researchers will compare rates of major birth defects and other infant health issues between vaccinated and unvaccinated women. The goal is to gather real-wor…

This study tests a program called HOP-STEP that helps doctors talk about pregnancy planning with women who have lupus. The goal is to make sure doctors document contraception use and pregnancy intentions during visits. The study involves 14 participants and is being tested at two…

This study was designed to follow women with rare autoimmune diseases (like lupus, arthritis, and scleroderma) during pregnancy to learn about complications and improve care. It was withdrawn before any participants were enrolled, so no results are available. The goal was to help…

This study looks at how lupus (SLE) is diagnosed, how it changes over time, and what treatments are used in everyday medical practice in Kazakhstan. About 509 adults with lupus will be followed to see how active their disease is, what medications they take, and how their health e…

This study is the first time a new drug, GSK4347859, is being tested in humans. The goal is to check its safety and how it behaves in the body. It involves 65 healthy adults and is currently on hold. The drug is being developed for lupus, an autoimmune disease.